Gentian Diagnostics ASA · OSL:GENT

Gentian Diagnostics ASA — Investor Presentation (December 2016)

22 slides from Gentian Diagnostics ASA's investor presentation, Dec 14, 2016

  1. Slide 1: Corporate presentation

    Slide 1: Corporate presentation

    Corporate presentation December 2016

  2. Slide 2: Improving Clinical Accuracy

    Slide 2: Improving Clinical Accuracy

    Improving Clinical Accuracy 1 Introduction 2 Existing business 3 Pipeline opportunities 4 Financials

  3. Slide 3: Building a leading diagnostics company

    Slide 3: Building a leading diagnostics company

    Building a leading diagnostics company Gentian Diagnostics  Team has previously founded Axis-Shield (sold to Alere for $ 367M)  Five tests on the market with international customer base  Significant pipeline including near-term launches  Fully funded for all planned development activities  Stro

  4. Slide 4: Medical diagnostics at a glance

    Slide 4: Medical diagnostics at a glance

    Medical diagnostics at a glance Results sent to Sample collection Transport to lab Analysis Diagnosis physician  Gentian develops reagent consumables for analytical instruments  Chemistry is instrument independent  Can be used on existing infrastructure

  5. Slide 5: Gentian operates in a highly attractive market

    Slide 5: Gentian operates in a highly attractive market

    COMPANY PRESENTATION Gentian operates in a highly attractive market Large (50 B USD) 19% 45% CAGR: 5.8% 24% Stable

  6. Slide 6: Gentian addresses unmet needs in the market

    Slide 6: Gentian addresses unmet needs in the market

    Gentian addresses unmet needs in the market Gentian R&D Faster results to New tests for patients better diagnostics Improving efficacy and costs for labs

  7. Slide 7: Introduction Existing business Pipeline opportunities

    Slide 7: Introduction Existing business Pipeline opportunities

    1 Introduction 2 Existing business 3 Pipeline opportunities 4 Financials

  8. Slide 8: Management team with track record

    Slide 8: Management team with track record

    Management team with track record The Management Team Bård Henrik Sundrehagen Erling Sundrehagen Ole Benny Østby Chief Executive Officer Chief Scientific Officer V.P. QA/RA  12 years Gentian  M.D. & PhD  3 years Gentian  9 years Axis-Shield  Founded Axis Shield in 1984,  QA Supervisor Axis-Shi

  9. Slide 9: Commercial stage company built step by step

    Slide 9: Commercial stage company built step by step

    Commercial stage company built step by step Proven R&D capabilities and commercial operations • Five products developed and launched • Total revenue of MNOK ~30 with gross margin of 70% • Positive cash flow ex R&D • Built significant pipeline

  10. Slide 10: Established infrastructure funded by existing products

    Slide 10: Established infrastructure funded by existing products

    Established infrastructure funded by existing products

  11. Slide 11: Launched products with global distribution

    Slide 11: Launched products with global distribution

    Launched products with global distribution  Cystatin C – Marker for diagnosis of early stage kidney disease – Distributed by Beckman Coulter and national market players  Fecal calprotectin – Marker for inflammatory bowel disease – Distributed by Bühlmann Lab’s, international market leader  NGAL –

  12. Slide 12: Improving Clinical Accuracy

    Slide 12: Improving Clinical Accuracy

    Improving Clinical Accuracy 1 Higher sensitivity => Higher volumes 2 New tests 3 Pipeline opportunities 4 Financials

  13. Slide 13: Highly efficient development process

    Slide 13: Highly efficient development process

    Highly efficient development process Development process 3.5 years Proof of concept Optimisation Verification Validation Launch 6 months 12 months 6 months 6 months 12 months Total average project cost: MNOK 8

  14. Slide 14: Selected pipeline projects

    Slide 14: Selected pipeline projects

    Selected pipeline projects  Plasma calprotectin – Test for early detection of inflammation – Potentially a superior marker for sepsis – Substantial unmet medical need – Launch in 2017  G-1001 – Current market size 2016E: c150 million tests performed annually – CAGR: 15% – Target launch 2018/19 – M

  15. Slide 15: Improving Clinical Accuracy

    Slide 15: Improving Clinical Accuracy

    Improving Clinical Accuracy 1 Higher sensitivity => Higher volume 2 New tests 3 New technologies 4 Financials

  16. Slide 16: Financials: Solid base with substantial upside

    Slide 16: Financials: Solid base with substantial upside

    Financials: Solid base with substantial upside 1 2 Base business Pipeline opportunity  Revenues of MNOK ~30  Expect to launch one product per year on  CAGR of 20% over the last 5 years average from 2017  Positive cash flow ex. R&D  Total pipeline addresses market of >$3bn/y  Solid cash positio

  17. Slide 17: Significant news flow expected

    Slide 17: Significant news flow expected

    Significant news flow expected  Proofs of concept  Product Launches  Quarterly reports  Significant Publications  Patent news  Sales contract and market penetrations

  18. Slide 18: Strategy supported by very strong shareholder base

    Slide 18: Strategy supported by very strong shareholder base

    Shareholderlist as of 12.12.2016 Strategy supported by very strong shareholder base Shareholder # of shares % shares Sundrehagen family 3 611 350 32,42 % Holta Life Sciences AS 1 928 496 17,31 % Rasmussengruppen AS 1 379 990 12,39 % Storebrand Vekst Verdipapirfond 1 030 420 9,25 % Kristianro AS, Eig

  19. Slide 19: Improving Clinical Accuracy

    Slide 19: Improving Clinical Accuracy

    Improving Clinical Accuracy

  20. Slide 20: Important notice

    Slide 20: Important notice

    Important notice  This presentation has been prepared by and is the sole responsibility of Gentian Diagnostics AS (the “Company” or “Gentian”). The presentation is furnished to you solely for your information and may not be reproduced or redistributed, in whole or in part, to any other person. The

  21. Slide 21: Questions?

    Slide 21: Questions?

    Questions?

  22. Slide 22: entian

    Slide 22: entian

    entian gen Clinical Accuracy

Source: Internet Archive copy of gentian.no

More decks from Gentian Diagnostics ASA

All 32 Gentian Diagnostics ASA decks